Chinese diagnostics firm WuXi Diagnostics raises $150m in Series B round
WuXi Diagnostics has developed a series of COVID-19 detection products. Source: WuXi Diagnostics
February 24, 2021
Chinese integrated diagnostics developer WuXi Diagnostics has raised $150 million in a Series B round of financing to advance its R&D pipeline and open-access innovation enabling platform, as the firm seeks to accelerate its market penetration in the global diagnostics sector.
The Series B round was backed by new investors including Thermo Fisher Scientific, the world’s largest maker of scientific instruments; healthcare-focused investment firm Shiyu Capital; ABC International, a wholly-owned subsidiary of Agricultural Bank of China; Sunland Capital, which focuses on early- and growth-stage healthcare investments; and equity investment fund CCBI Tech Venture.